GSK Pharmaceuticals India has named Ronojit Biswas as its new Chief Financial Officer, succeeding Juby Chandy who has been elevated to a broader Asia-Pacific finance leadership position within the GSK group. The leadership change strengthens the company’s financial strategy and governance as it continues to expand its vaccines, specialty medicines, and consumer healthcare portfolio in one of the world’s fastest-growing pharma markets.
Glimpse:
The transition, effective February 1, 2026, sees Ronojit Biswas previously Vice President, Finance at GSK India assume the CFO role with responsibility for financial planning, controllership, treasury, taxation, investor relations, and risk management. Juby Chandy moves to a regional APAC finance leadership position, overseeing financial operations and strategy across multiple high-growth markets. Both executives bring deep GSK tenure and proven expertise in navigating India’s complex regulatory and commercial environment.
GSK Pharmaceuticals India has announced a key leadership transition with the appointment of Ronojit Biswas as Chief Financial Officer, effective February 1, 2026. Biswas succeeds Juby Chandy, who has been elevated to a senior finance leadership role covering the Asia-Pacific region within the global GSK organisation.
Ronojit Biswas has been with GSK India for over a decade, most recently serving as Vice President Finance, where he played a pivotal role in driving financial discipline, optimising cost structures, strengthening compliance frameworks, and supporting the company’s aggressive growth in vaccines, specialty medicines (oncology, immunology, respiratory), and consumer healthcare. His appointment ensures continuity in financial strategy while bringing fresh perspectives to capital allocation, operational efficiency, and long-term value creation in India’s dynamic pharma market.
Juby Chandy, who has served as CFO of GSK India since 2020, will now take on a broader mandate overseeing finance operations and strategy for the Asia-Pacific cluster. During her tenure, Chandy led GSK India through significant milestones including strong double digit growth, successful launches of key therapies, and enhanced investor confidence while navigating complex regulatory changes and macroeconomic headwinds.
GSK India Managing Director commented: “Ronojit’s deep understanding of our business, combined with his strategic financial acumen, makes him the ideal leader to guide GSK India through its next phase of growth. We also congratulate Juby on her well-deserved elevation to a regional role she has left an indelible mark on our India operations and will continue to contribute significantly to GSK’s APAC success.”
The leadership change comes at a transformative time for GSK India, which is investing heavily in vaccines (including Shingrix and new pipeline assets), specialty medicines, and digital capabilities to strengthen its position in one of the world’s fastest-growing pharmaceutical markets. The company remains focused on innovation, access expansion through public-private partnerships, and delivering sustainable growth while maintaining the highest standards of compliance and governance.
“Finance is not just about numbers it’s about enabling bold innovation, ensuring sustainable growth, and delivering value to patients and shareholders. I am honoured to lead this function at such an exciting time for GSK in India.”
By
HB Team
Related News
